Tumor Chemosensitization through Oncogene Knockdown Mediated by Unique α-Tocopherylated Cationic Geminis

Area of Science:

• Biotechnology
• Nanomedicine
• Cancer Research

Background:

• siRNA delivery remains a challenge in cancer therapy.
• Gemini lipids offer potential for enhanced nucleic acid delivery.
• Targeting oncogenes like survivin is crucial for tumor regression.

Purpose of the Study:

• To evaluate the siRNA transfection efficiency of novel α-tocopherylated gemini lipids.
• To assess the efficacy of these lipids in silencing oncogenes in vitro and in vivo.
• To investigate their potential for tumor regression through chemosensitization and suicide gene therapy.

Main Methods:

• siRNA transfection using α-tocopherylated gemini lipids (TH8S and T8S) in vitro and in vivo.
• Assessment of oncogene silencing (survivin) and p53 upregulation.
• Evaluation of tumor regression and chemosensitization to doxorubicin in a murine model.

Main Results:

• TH8S gemini lipid demonstrated higher siRNA transfection efficacy than T8S.
• Effective oncogene silencing (survivin mRNA reduction) in xenograft tumors.
• Enhanced sensitivity of cancer cells and tumors to doxorubicin treatment.
• Significant inhibition of tumor growth in vivo.

Conclusions:

• α-tocopherylated gemini lipids, particularly TH8S, are efficient siRNA delivery vehicles.
• Anti-survivin siRNA delivered via TH8S co-liposomes promote tumor regression and chemosensitization.
• This strategy represents a potent approach for cancer management via suicide gene therapy.